Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Periodontitis is a multifactorial disease of the periodontium that can lead to destruction of the alveolar bone and supporting connective tissue and subsequent tooth loss. Recent studies have shown that periodontitis is associated with age, smoking habits, genetic predisposition, socioeconomic status, and various systemic diseases such as diabetes mellitus, atherosclerosis, obesity, osteoporosis, and rheumatoid arthritis (RA). RA is a chronic, systemic inflammatory disease of unknown etiology that primarily affects the joints. Periodontitis and RA have similar clinical and pathogenic features. Clinically, both diseases are characterized by local destruction of hard and soft tissues. Their pathogenesis involves the release of cytokines and matrix metalloproteinases (MMPs) from inflammatory cells. Expression of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) leads to the release of high levels of inflammatory mediators that cause bone destruction and the spread of inflammation. TNF-α is the main regulatory cytokine in both RA and periodontitis. TNF-α inhibitors (anti-TNF-α) reduce the number of inflammatory cells, osteoclast formation and bone loss. In addition, many immunological processes have been identified that are similar to both diseases. Autoreactive T cells, natural killer cells, heat shock proteins, autoantibodies and genetic factors are reported to play an important role in the inflammatory pathway of RA and periodontitis.
Recently, TNF-α blocking agents (anti-TNF-α) have been developed and used for the treatment of RA. Animal and human studies have suggested that anti-TNF-α treatment may reduce the severity of periodontitis.
The aim of this study was to investigate the effect of nonsurgical periodontal treatment combined with anti-TNF-α on alveolar bone loss and oxidative stress in individuals with RA and periodontitis.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| control | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Non Surgical Periodontal Treatment | Procedure | This procedure will be applied to all patients. All patients received nonsurgical periodontal treatment. Scaling root planing and subgingival debridement were performed. |
| Measure | Description | Time Frame |
|---|---|---|
| Periodontal pocket depth | The distance between the pocket base and the gingival margin is measured | baseline, 3rd month after non-surgical periodontal therapy, 6th month after non-surgical periodontal therapy |
| clinical attachment loss | The distance between the pocket base and the cementoenamel junction is measured | baseline, 3rd month after non-surgical periodontal therapy, 6th month after non-surgical periodontal therapy |
| Measure | Description | Time Frame |
|---|---|---|
| serum and GCF receptor activator nuclear kappa B ligand (RANKL) level | RANKL levels in serum and GCF will be measured with biochemical kits. | baseline, after non-surgical periodontal therapy at 3 months, after non-surgical periodontal therapy at 6 months, |
| serum and GCF osteoprotegrin (OPG) level |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Recep Tayyip Erdoğan University Faculty of Dentistry | Rize | 53020 | Turkey (Türkiye) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 18050377 | Result | de Pablo P, Dietrich T, McAlindon TE. Association of periodontal disease and tooth loss with rheumatoid arthritis in the US population. J Rheumatol. 2008 Jan;35(1):70-6. Epub 2007 Nov 15. | |
| 42129776 | Derived | Yemenoglu H, Beder M, Cure O, Kose O, Arpa M, Atak M, Bostan SA. The effect of anti-tumor necrosis factor-alpha and nonsurgical periodontal therapy in individuals with rheumatoid arthritis. BMC Oral Health. 2026 May 13. doi: 10.1186/s12903-026-08538-6. Online ahead of print. |
Not provided
Not provided
The requested data can be shared in a way that protects patient personal information.
1 year as of 02.02.2025
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Periodontal measurements will be performed | Other | Periodontal measurements will be performed on all patients (plaque index, gingival index, bleeding on probing, periodontal pocket depth, clinical attachment loss). |
|
| biochemical measurements | Other | Serum and gingival crevicular fluid (GCF) samples will be collected from patients for biochemical evaluations. |
|
| No medication will be administered to patients. | Other | No medication will be administered to patients. |
|
OPG levels in serum and GCF will be measured with biochemical kits. |
| baseline, after non-surgical periodontal therapy at 3 months, after non-surgical periodontal therapy at 6 months, |
| serum and GCF matrix metalloproteinase 8 (MMP8) level | MMP-8 levels in serum and GCF will be measured with biochemical kits. | baseline, after non-surgical periodontal therapy at 3 months, after non-surgical periodontal therapy at 6 months, |
| serum total antioxidant status (TAS) level | TAS levels in serum will be measured with biochemical kits. | baseline, after non-surgical periodontal therapy at 3 months, after non-surgical periodontal therapy at 6 months, |
| serum total oxidant status (TAS) level | TOS levels in serum will be measured with biochemical kits. | baseline, after non-surgical periodontal therapy at 3 months, after non-surgical periodontal therapy at 6 months, |
| ID | Term |
|---|---|
| D012213 | Rheumatic Fever |
| D001172 | Arthritis, Rheumatoid |
| D010510 | Periodontal Diseases |
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D013290 | Streptococcal Infections |
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided